Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

November 30, 2025

Study Completion Date

April 30, 2034

Conditions

Prostate Cancer MetastaticProstate Cancer

Interventions

DRUG

Abiraterone Acetate

1000 mg orally daily until disease progression

DRUG

Prednisone

5 mg oral low dose prednisone, twice daily

Trial Locations (3)

RECRUITING

Ben Taub General Hospital, Houston

RECRUITING

Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston

RECRUITING

Michael E. DeBakey Veterans Affairs Medical Center, Houston

All Listed Sponsors

lead

Martha Mims

OTHER